

STN SEARCH
NOTES 10/663,082

=> d his

(FILE 'HOME' ENTERED AT 12:59:57 ON 01 JUN 2005)

FILE 'HCAPLUS' ENTERED AT 13:00:21 ON 01 JUN 2005

E 20020004521/PN
E US20020004521/PN
E US20030133978/PN
E US20040029859/PN

L1 1 S E3
E US20030133978/PN
L2 1 S E3
L3 2 S L1 OR L2

FILE 'MEDLINE, HCAPLUS, BIOSIS, EMBASE' ENTERED AT 13:04:26 ON 01 JUN 2005

L4 29888 S HMG(W)COA OR ATORVASTATIN
L5 163204 S A(3A) (ADRENERGIC OR ADRENO?)
L6 156 S L4 AND L5
L7 73 S L6 AND ATORVASTATIN
L8 3 S (L6 OR L7) AND SYNERG?

=> d l3 1-2

L3 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:737747 HCAPLUS
DN 139:261314
TI Preparation of alkoxy quinazolinone compounds as α 1L adrenoceptors
antagonists useful in therapy
IN Blagg, Julian; Fray, Michael Jonathan; Lewis, Mark Llewellyn; Mathias,
John Paul; Stefaniak, Mark Henryk; Stobie, Alan
PA Pfizer Limited, UK; Pfizer Inc.
SO PCT Int. Appl., 247 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003076427	A1	20030918	WO 2003-IB998	20030305
	WO 2003076427	C1	20041007		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2479016	AA	20030918	CA 2003-2479016	20030305
	EP 1483257	A1	20041208	EP 2003-743965	20030305
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003008407	A	20050111	BR 2003-8407	20030305
	US 2004029859	A1	20040212	US 2003-387106	20030312 <--
PRAI	GB 2002-6033	A	20020314		
	US 2002-374894P	P	20020423		
	WO 2003-IB998	W	20030305		
OS	MARPAT 139:261314				
RE.CNT 3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L3 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2003:319686 HCAPLUS
 DN 138:343870
 TI Pharmaceutical formulations for the controlled release of
 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-
 2-yl)-5-(2-pyridyl) quinazoline
 IN Davis, John Douglas; Humphrey, Michael John; MacRae, Ross James; Smith,
 Janet Sarah
 PA Pfizer Limited, UK; Pfizer Inc.
 SO PCT Int. Appl., 34 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003032956	A1	20030424	WO 2002-IB4040	20020930
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2461168	AA	20030424	CA 2002-2461168	20020930
	EP 1434570	A1	20040707	EP 2002-775048	20020930
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002013196	A	20040831	BR 2002-13196	20020930
	JP 2005507909	T2	20050324	JP 2003-535760	20020930
	US 2003133978	A1	20030717	US 2002-269551	20021010 <--
PRAI	GB 2001-24455	A	20011011		
	US 2001-340717P	P	20011030		
	WO 2002-IB4040	W	20020930		
RE.CNT	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

=> d 18 1-3

L8 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2001:816444 HCAPLUS
 DN 135:352829
 TI Combination therapeutic compositions containing benzene compounds
 IN Jaen, Juan C.; Chen, Jin-Long
 PA Tularik Inc., USA
 SO PCT Int. Appl., 57 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001082916	A2	20011108	WO 2001-US14393	20010502
	WO 2001082916	A3	20020704		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				

SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
 YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002037928 A1 20020328 US 2001-847887 20010502
 US 6653332 B2 20031125
 US 2004259918 A1 20041223 US 2003-456932 20030605
 PRAI US 2000-201613P P 20000503
 US 2001-847887 A1 20010502
 OS MARPAT 135:352829

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1999:184130 HCAPLUS
 DN 130:205139
 TI Combination therapy comprising atorvastatin and an
 antihypertensive agent
 IN Scott, Robert Andrew Donald
 PA Pfizer Inc., USA
 SO PCT Int. Appl., 51 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9911260	A1	19990311	WO 1998-IB1230	19980811
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
	DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,				
	KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,				
	NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,				
	UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,				
	FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,				
	CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2296723	AA	19990311	CA 1998-2296723	19980811
	AU 9884589	A1	19990322	AU 1998-84589	19980811
	AU 740424	B2	20011101		
	EP 1009400	A1	20000621	EP 1998-935250	19980811
	EP 1009400	B1	20041229		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
	SI, LT, LV, FI, RO				
	TR 200000563	T2	20000721	TR 2000-200000563	19980811
	BR 9811556	A	20000822	BR 1998-11556	19980811
	JP 2001514223	T2	20010911	JP 2000-508363	19980811
	NZ 502280	A	20021126	NZ 1998-502280	19980811
	CN 1473566	A	20040211	CN 2003-2003143092	19980811
	CN 1473567	A	20040211	CN 2003-2003143093	19980811
	AT 285767	E	20050115	AT 1998-935250	19980811
	EP 1514543	A1	20050316	EP 2004-23093	19980811
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
	SI, LT, LV, FI, RO, MK, CY, AL				
	AP 1191	A	20030719	AP 1998-1332	19980827
	W: BW, GM, KE, MW, UG, ZM, ZW				
	ZA 9807839	A	20000228	ZA 1998-7839	19980828
	NO 2000000996	A	20000427	NO 2000-996	20000228
	US 2002099046	A1	20020725	US 2001-45329	20011023
	US 2003199492	A1	20031023	US 2003-442285	20030519
	JP 2005041875	A2	20050217	JP 2004-214382	20040722
PRAI	US 1997-57276P	P	19970829		
	EP 1998-935250	A3	19980811		
	JP 2000-508363	A3	19980811		
	WO 1998-IB1230	W	19980811		

US 2000-513887 B1 20000225

US 2001-45329 B1 20011023

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 3 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN
AN 2003002454 EMBASE
TI Lipid lowering: Another method of reducing blood pressure?.
AU Wierzbicki A.S.
CS A.S. Wierzbicki, Lipid Unit, Department of Chemical Pathology, St. Thomas'
Hospital, Lambeth Palace Road, London SE1 7EH, United Kingdom
SO Journal of Human Hypertension, (1 Nov 2002) Vol. 16, No. 11, pp. 753-760.
Refs: 80
ISSN: 0950-9240 CODEN: JHHYEN
CY United Kingdom
DT Journal; General Review
FS 018 Cardiovascular Diseases and Cardiovascular Surgery
029 Clinical Biochemistry
017 Public Health, Social Medicine and Epidemiology
005 General Pathology and Pathological Anatomy
037 Drug Literature Index
030 Pharmacology
LA English
SL English
ED Entered STN: 20030109
Last Updated on STN: 20030109

=> d 3 bib ab

L8 ANSWER 3 OF 3 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN
AN 2003002454 EMBASE
TI Lipid lowering: Another method of reducing blood pressure?.
AU Wierzbicki A.S.
CS A.S. Wierzbicki, Lipid Unit, Department of Chemical Pathology, St. Thomas'
Hospital, Lambeth Palace Road, London SE1 7EH, United Kingdom
SO Journal of Human Hypertension, (1 Nov 2002) Vol. 16, No. 11, pp. 753-760.
Refs: 80
ISSN: 0950-9240 CODEN: JHHYEN
CY United Kingdom
DT Journal; General Review
FS 018 Cardiovascular Diseases and Cardiovascular Surgery
029 Clinical Biochemistry
017 Public Health, Social Medicine and Epidemiology
005 General Pathology and Pathological Anatomy
037 Drug Literature Index
030 Pharmacology
LA English
SL English
ED Entered STN: 20030109
Last Updated on STN: 20030109
AB Modern management of cardiovascular risk depends on assessment of
cardiovascular risk factors. Hypertension and hyperlipidaemia are
synergistic risk factors for cardiovascular events. Both show a
degree of cross-correlation through sharing mechanisms of pathogenesis
including insulin resistance and endothelial dysfunction. This article
reviews the common pathways leading to dyslipidaemia and hypertension and
the effects diet and lipid-lowering drug therapies have had on correcting
blood pressure in patients with essential hypertension. Both statins and
fibrates have shown a capability to lower blood pressure by up to 8/5 and
15/10 mmHg respectively, in some small-scale clinical trials and have

effects on arterial walls structure and hence pulse wave velocity. This blood pressure action may account for some of the clinical effects of lipid-lowering drugs on cardiovascular risk. Thus, lipid lowering may provide an additional method of correcting hypertension in some high-risk patients. However, data from large-scale intervention trials are either absent or ambiguous. Definitive large-scale trials to investigate the antihypertensive effects of lipid-lowering drugs are required, although end point studies examining the interaction of lipid-lowering and antihypertensive drugs to determine optimum combinations are already under way.

STN SEARCH
NOTES 10/663,082

=> d his

(FILE 'HOME' ENTERED AT 12:22:00 ON 01 JUN 2005)

FILE 'REGISTRY' ENTERED AT 12:22:08 ON 01 JUN 2005

L1 374 S CYCLOPROPYL AND METHOXY AND MORPHOLIN?
L2 27 S L1 AND YLMETHYL
L3 7 S L2 AND DIHYDRO

FILE 'MEDLINE, HCAPLUS, BIOSIS, EMBASE' ENTERED AT 12:23:54 ON 01 JUN 2005

L4 5 S L3